Raymond James lowered the firm’s price target on Apellis (APLS) to $50 from $52 and keeps an Outperform rating on the shares following the Q2 earnings, citing the firm’s “bullish” outlook for the newly-approved expansion indications for Empaveli and evidence the Syfovre launch is getting back on track. The Empaveli FDA label was expanded to include broad coverage of C3G and IC-MPGN patients 12 and older, which could expand the Empaveli addressable patient population by about 75%, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals
- Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion
- Apellis price target raised to $52 from $46 at Citi
- Apellis Pharmaceuticals Reports Q2 2025 Earnings
- Apellis price target raised to $26 from $24 at Goldman Sachs